石四藥集團(02005.HK):阿比多爾被中國國家衞生健康委員會列入《流行性感冒診療方案》(2020年版)
格隆匯 11 月 5日丨石四藥集團(02005.HK)發佈公告,集團產品阿比多爾被中國國家衞生健康委員會列入於2020年11月4日發佈的《流行性感冒診療方案》(2020年版)。根據該診療方案,阿比多爾被用於成人甲、乙型流感的治療。
誠如公司此前公告所載,集團擁有在中國生產阿比多爾原料藥和製劑的領先公司。阿比多爾為廣譜抗病毒藥物,通過抑制病毒和宿主細胞膜的融合,從而阻斷病毒感染的第一步。此外,阿比多爾還可誘導機體產生內源性干擾素,在干擾病毒複製的同時,亦能調節增強機體免疫功能。具有多重機制抗擊病毒的獨特優勢。2019年首次納入國家醫保目錄和納入國家衞生健康委員會發布的抗病毒流感臨牀推薦使用藥物名單。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.